The stocks of ABT have been issued with a rating of buy by twenty different brokerages that have covered the firm. Currently one of the investment analysts has issued the company with a rating of sell, while two others have issued the company with a rating of hold. Close to sixteen other analysts have provided the company with a rating of buy. Currently, the price target of the company is $122.
The Stock Commentary Of ABT
There have been quite a few research equities that have commented on the stocks of ABT. Atlantic Securities has already covered the stocks of the company with a rating of neutral and a price target of $122 in a 15th April research report. Barclays has also reduced the price target of the company from $150 to $125 with a rating of overweight in a 2nd June research report.
Raymond James has also reduced the price target of the company from $130 to $116 with a rating of outperform in a 2nd June research report. Wells Fargo has reduced the price target of the company from $137 to $125 with a rating of overweight in a 2nd June research report. In the end, William Blair came up with a rating of outperform in a 20th April research report.
The stocks of ABT traded on Thursday at $110.84. The moving average price of the company over a period of 50 days is $116.05. The market cap of the company is $196.94 billion, with a 34.75 PE ratio, along with a 2.17 PEG ratio. The year low of the company is $86.16, with a year high of around $128.54. The debt-to-equity ratio of the company is 0.52, with a 1.75 current ratio.
ABT previously released its quarterly report on the 19th of April. The maker of healthcare products reported an EPS of $1.32 with the consensus estimate coming to $1.27. The revenue generated by the company during this period was $10.45 billion which was slightly less than the consensus estimate of $10.72 billion.